MIRA Pharmaceuticals reports that its novel oral ketamine analog, Ketamir-2, demonstrated 60% greater efficacy than FDA-approved gabapentin in a preclinical model of chemotherapy-induced neuropathic pain. This result builds on previous preclinical successes, further establishing Ketamir-2's potential as a breakthrough treatment for neuropathic pain.The company is advancing its development program with additional studies targeting diabetic neuropathy and PTSD. MIRA is also exploring government funding opportunities to support the program as part of its broader strategy. These developments signify potential progress in addressing unmet needs in pain management and mental health treatment.

MIRA Pharmaceuticals reports that its novel oral ketamine analog, Ketamir-2, demonstrated 60% greater efficacy than FDA-approved gabapentin in a preclinical model of chemotherapy-induced neuropathic pain. This result builds on previous preclinical successes, further establishing Ketamir-2's potential as a breakthrough treatment for neuropathic pain.The company is advancing its development program with additional studies targeting diabetic neuropathy and PTSD. MIRA is also exploring government funding opportunities to support the program as part of its broader strategy. These developments signify potential progress in addressing unmet needs in pain management and mental health treatment.